Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2, Open-label, Multinational Clinical Study to Evaluate the Safety and Efficacy of BMN 110 in Pediatric Patients Less Than 5 Years of Age With Mucopolysaccharidosis IVA (Morquio A Syndrome)

NCT01515956 is registered in ClinicalTrials.gov with BioMarin Pharmaceutical as lead sponsor.

NCT NCT01515956
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01515956 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2, Open-label, Multinational Clinical Study to Evaluate the Safety and Efficacy of BMN 110 in Pediatric Patients Less Than 5 Years of Age With Mucopolysaccharidosis IVA (Morquio A Syndrome)
Lead sponsor
BioMarin Pharmaceutical
Phase
Phase 2
Overall status
Completed
Start date
October 31, 2011
Completion date
February 29, 2016
Enrollment
15 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

morquio a syndrome, mps iva, mucopolysaccharidosis iva